What are the signs of hepatotoxicity associated with amphotericin B and what is the recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amphotericin B Hepatotoxicity: Recognition and Management

Hepatotoxicity with amphotericin B is uncommon but documented, manifesting primarily as asymptomatic elevations in liver enzymes (alkaline phosphatase, AST, ALT, bilirubin) that typically resolve upon drug discontinuation. 1

Clinical Presentation and Monitoring

Signs of Hepatotoxicity

The FDA label explicitly recommends monitoring liver function regularly during amphotericin B therapy 1. Hepatotoxicity typically presents as:

  • Asymptomatic elevation of liver enzymes (most common presentation) 2
  • Increased alkaline phosphatase, AST, ALT, LDH, and bilirubin 2
  • Rarely progresses to clinically significant liver dysfunction 3

The incidence of hepatotoxicity ranges from 18-23% in reported series, though severe acute or subacute hepatotoxicity is very rare 4, 3. Importantly, hepatotoxicity is reversible in the vast majority of cases when the drug is discontinued 5, 2.

Monitoring Protocol

Based on FDA guidance and clinical evidence 1:

  • Baseline liver function tests before initiating therapy
  • Regular monitoring of liver enzymes during treatment (specific intervals at 1,2, and 4 weeks, then every 3 months have been recommended for azoles 6; similar vigilance is prudent for amphotericin B)
  • Monitor hepatic function alongside renal function, serum electrolytes (magnesium and potassium), blood counts, and hemoglobin 1

Risk Factors and Clinical Context

High-Risk Scenarios

Exercise particular caution in patients with:

  • Pre-existing hepatic injury or dysfunction 4
  • Concomitant use of other hepatotoxic agents, including azole antifungals (itraconazole, fluconazole) 5
  • Critically ill patients where distinguishing drug-induced hepatotoxicity from illness-related liver abnormalities may be challenging 3
  • Immunocompromised patients receiving chemotherapy (though most reports are in this population, immunocompetent patients can also develop hepatotoxicity) 4

Important Consideration

The evidence suggests amphotericin B may interfere with hepatic cytochrome P450, potentially affecting the liver's metabolic capacity 3. This raises concern for drug interactions during prolonged treatment, particularly with medications undergoing hepatic metabolism.

Management Approach

When Hepatotoxicity Develops

Discontinue amphotericin B immediately if significant hepatotoxicity occurs 5, 2. The evidence consistently demonstrates:

  • Rapid resolution of liver enzyme elevations upon drug discontinuation 5, 2
  • Rechallenge at lower doses may still trigger recurrent hepatotoxicity 2
  • Alternative antifungal therapy should be considered rather than rechallenge

Alternative Formulations

Liposomal amphotericin B (L-AMB) may be considered as an alternative, though hepatotoxicity has been reported with lipid formulations as well 7, 8. In one study, 21% of patients receiving L-AMB developed hepatotoxicity, though no specific correlates (age, dose escalation, cumulative dose) were significantly associated with its occurrence 7.

Practical Algorithm

  1. Detect elevation: Monitor liver enzymes regularly during therapy
  2. Assess severity: Determine if elevation is mild (continue with close monitoring) or significant (>3x upper limit of normal for transaminases or bilirubin >1.5 mg/dL)
  3. Evaluate causality: Rule out other causes (underlying disease, other medications, sepsis)
  4. If significant hepatotoxicity confirmed:
    • Discontinue amphotericin B immediately
    • Switch to alternative antifungal (azole or echinocandin based on organism susceptibility)
    • Monitor liver enzymes for resolution
    • Do not rechallenge with amphotericin B if severe hepatotoxicity occurred

Critical Pitfalls

  • Do not assume liver abnormalities are solely due to underlying illness in critically ill patients; amphotericin B can contribute 3
  • Avoid combining amphotericin B with other hepatotoxic agents when possible, particularly azole antifungals 5
  • Do not overlook the need for baseline liver function assessment before starting therapy 1
  • Remember that lipid formulations are not completely free of hepatotoxicity risk, though they have improved safety profiles overall 7

References

Research

Reversible hepatotoxicity related to amphotericin B.

Canadian Medical Association journal, 1984

Research

Amphotericin B and liver function.

European journal of internal medicine, 2002

Research

Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient.

Journal of pharmacology & pharmacotherapeutics, 2016

Research

Hepatotoxicity possibly caused by amphotericin B.

The Annals of pharmacotherapy, 1999

Research

An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.